GREG M. DELGOFFE, PHD
Dr. Delgoffe is Professor of Immunology at the University of Pittsburgh, Associate Director for Basic Research and Director of the Tumor Microenvironment Center at the UPMC Hillman Cancer Center. Since its inception, Dr. Delgoffe’s lab has worked to both understand how immune cells alter their functional and differentiation state through integration of metabolic cues, most notably in cancer. He studies how immune cells become metabolically deficient as they infiltrate tumors and leverage that insight into metabolic strategies to bolster immunotherapy for cancer. He has received multiple awards lauding the innovative aspects of his research program, including the NIH Director’s New Innovator Award, the Mark Foundation for Cancer Research Emerging Leader Award, the AACR NextGen Star award, and the Cancer Research Institute’s Lloyd J. Old STAR Award. He is a Senior Member of the National Academy of Inventors and has been a Clarivate Highly Cited Researcher in Immunology since 2022. Moreover, much of his work has been translated into novel therapeutics or clinical trials, both repurposing metabolic drugs as well as developing novel synthetic biology approaches to immunometabolically improve cancer therapy, most notably in checkpoint blockade, oncolytic virus, and adoptive cell therapies.